GSK plc
GLAXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $2,951,000 | $5,308,000 | $4,921,000 | $5,096,000 |
| Dep. & Amort. | $2,551,000 | $2,294,000 | $2,298,000 | $2,524,000 |
| Deferred Tax | $0 | $0 | -$1,236,000 | -$318,000 |
| Stock-Based Comp. | $344,000 | $307,000 | $346,000 | $343,000 |
| Change in WC | $2,090,000 | -$364,000 | $271,000 | -$473,000 |
| Other Non-Cash | -$1,382,000 | -$777,000 | $803,000 | $756,000 |
| Operating Cash Flow | $6,554,000 | $6,768,000 | $7,403,000 | $7,952,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,399,000 | -$1,314,000 | -$2,258,000 | -$2,931,000 |
| Net Acquisitions | $1,368,000 | -$1,384,000 | -$3,136,000 | $185,000 |
| Inv. Purchases | $0 | $0 | -$703,000 | $1,759,000 |
| Inv. Sales/Matur. | $21,000 | $72,000 | $1,000 | $18,000 |
| Other Inv. Act. | -$1,219,000 | $1,031,000 | -$2,676,000 | -$808,000 |
| Investing Cash Flow | -$1,229,000 | -$1,595,000 | -$8,772,000 | -$1,777,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$1,166,000 | -$2,370,000 | -$4,622,000 | -$2,003,000 |
| Stock Issued | $20,000 | $10,000 | $25,000 | $21,000 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$2,444,000 | -$2,247,000 | -$3,467,000 | -$3,999,000 |
| Other Fin. Act. | -$1,136,000 | -$1,034,000 | $8,887,000 | -$1,608,000 |
| Financing Cash Flow | -$4,726,000 | -$5,641,000 | $823,000 | -$7,589,000 |
| Forex Effect | -$54,000 | -$99,000 | $152,000 | -$29,000 |
| Net Chg. in Cash | $545,000 | -$567,000 | -$394,000 | -$1,443,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,858,000 | $3,425,000 | $3,819,000 | $5,262,000 |
| End Cash | $3,403,000 | $2,858,000 | $3,425,000 | $3,819,000 |
| Free Cash Flow | $3,572,000 | $4,424,000 | $5,145,000 | $5,021,000 |